Epigenomics, Qiagen Ink Colorectal Cancer Option Deal
February 28, 2011
Epigenomics, Qiagen Ink Colorectal Cancer Option Deal
The agreement enables Qiagen to develop a colorectal cancer blood test based on Epigenomics' mSept9 biomarker and certain DNA methylation analysis technologies.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.